Pharmaceutical

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Regeneron and Sanofi's Dupixent has been approved for the treatment of chronic spontaneous urticaria (CSU) or itching in Japan.

Feb 16, 2024 - 18:00
Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan
Regeneron and Sanofi's Dupixent has been approved for the treatment of chronic spontaneous urticaria (CSU) or itching in Japan.
Read the original article

Tags:

Previous Article

QBiotics wins FDA orphan status for rainforest-derived cancer drug

Next Article

Dragonfly and Gilead enter partnership for cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sen. Bernie Sanders moves toward another hearing with pharma CEOs

Sen. Bernie Sanders moves toward another hearing with p...

Nov 7, 2023

Moderna reports $1.2bn net loss in Q1 2024

Moderna reports $1.2bn net loss in Q1 2024

May 5, 2024

2023 Nobel Prize in Medicine: Karikó, Weissman awarded prize for mRNA research

2023 Nobel Prize in Medicine: Karikó, Weissman awarded ...

Oct 2, 2023